{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:39:43Z","timestamp":1789720783421,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.058","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T15:38:45Z","timestamp":1675265925000},"page":"1623-1631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries"],"prefix":"10.1016","volume":"41","author":[{"given":"Abraham M.","family":"Getaneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuxin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline K.","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jojanneke","family":"van Summeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Phijffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van Wijhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terho","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Bilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.058_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.058_b0010","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1093\/infdis\/jiaa360","article-title":"Respiratory syncytial virus-associated hospital admissions in children younger than 5 years in 7 European countries using routinely collected datasets","volume":"222","author":"Reeves","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.058_b0015","unstructured":"European Medicines Agency. Synagis (palivizumab) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/synagis-epar-product-information_en.pdf. Accessed 12\/September\/2021"},{"key":"10.1016\/j.vaccine.2023.01.058_b0020","unstructured":"British National Formulary (BNF). palivizumab. http:\/\/www.bnf.org.uk, Accessed 01\/June\/2022"},{"key":"10.1016\/j.vaccine.2023.01.058_b0025","unstructured":"YiopistonApteekki. SYNAGIS INJEKTIONESTE 50MG\/0,5ML. https:\/\/www.yliopistonapteekki.fi\/synagis-injektioneste-50mg-0-5ml-rx Accessed 01\/June\/2022"},{"key":"10.1016\/j.vaccine.2023.01.058_b0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.058_b0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jinf.2013.11.013","article-title":"The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy","volume":"68","author":"Cromer","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.01.058_b0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","article-title":"Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis","volume":"18","author":"Hodgson","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.01.058_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac064","article-title":"Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children","author":"Li","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.058_b0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12916-020-01537-6","article-title":"Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries","volume":"18","author":"Li","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.01.058_b0055","doi-asserted-by":"crossref","first-page":"e046563","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model","volume":"11","author":"Baral","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2023.01.058_b0060","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2021.06.086","article-title":"Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: a modeling study to inform policy and investment decisions","volume":"39","author":"Laufer","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.058_b0065","article-title":"Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: a case study of Nunavik","volume":"41","author":"Nourbakhsh","year":"2021","journal-title":"Canada EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2023.01.058_b0070","article-title":"Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities","author":"Liu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.058_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac150","article-title":"Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European Countries: a time series analysis","author":"Johannesen","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.058_b0080","unstructured":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomic Guidelines Around The World. 2022. https:\/\/tools.ispor.org\/peguidelines\/ Accessed 11\/January\/2022"},{"key":"10.1016\/j.vaccine.2023.01.058_b0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0272989X11409240","article-title":"Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide","volume":"31","author":"Bilcke","year":"2011","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2023.01.058_b0090","doi-asserted-by":"crossref","unstructured":"Briggs AC, K. Sculpher, M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"10.1016\/j.vaccine.2023.01.058_b0095","unstructured":"van Summeren J, Kwakkelstein, Hooiveld M, Hendriksen, Caini, Korevaar, et al. RSV ComNet I: disease burden of RSV infections in young children (<5 years) in primary care. Results of the pilot study in Italy & the Netherlands winter of 2019\/20. Utrecht: Nivel; 2022."},{"key":"10.1016\/j.vaccine.2023.01.058_b0100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.058_b0105","article-title":"WHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines. Biologicals DoIVa","year":"2017","journal-title":"Geneva"},{"key":"10.1016\/j.vaccine.2023.01.058_b0110","unstructured":"Pfizer. Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate. 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-data-phase-3-global Accessed 01\/November\/2022"},{"key":"10.1016\/j.vaccine.2023.01.058_b0115","article-title":"Costs and health-related quality of life of respiratory syncytial virus (RSV) infection among infants and their caregivers in Europe (under revision)","author":"Mao","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.058_b0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jval.2020.02.011","article-title":"A review of the methods used to generate utility values in NICE technology assessments for children and adolescents","volume":"23","author":"Hill","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2023.01.058_b0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0272989X211045070","article-title":"Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice","volume":"42","author":"Bilcke","year":"2022","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2023.01.058_b0130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jval.2019.02.008","article-title":"\u201cTime Traveling Is Just Too Dangerous\u201d but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier","volume":"22","author":"Alarid-Escudero","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2023.01.058_b0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00019053-200927040-00002","article-title":"Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources","volume":"27","author":"Bilcke","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2023.01.058_b0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/irv.12686","article-title":"Estimates for quality of life loss due to Respiratory Syncytial Virus","volume":"14","author":"Hodgson","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2023.01.058_b0145","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0272989X14566013","article-title":"Quantifying parameter and structural uncertainty of dynamic disease transmission models using MCMC: an application to rotavirus vaccination in England and Wales","volume":"35","author":"Bilcke","year":"2015","journal-title":"Med Decis Making"},{"issue":"22","key":"10.1016\/j.vaccine.2023.01.058_b9000","first-page":"04746-5","article-title":"Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study","volume":"S1098\u20133015","author":"Li","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2023.01.058_b0150","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100639","article-title":"Low levels of respiratory syncytial virus activity in Europe during the 2020\/21 season: what can we expect in the coming summer and autumn\/winter?","volume":"26","author":"van Summeren","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2023.01.058_b0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/jpids\/piaa094","article-title":"Respiratory syncytial virus-associated acute otitis media in infants and children","volume":"9","author":"Phillips","year":"2020","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:17Z","timestamp":1759404197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000920"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}